Skip to main content

Table 5 Correlation analysis of SCC antigen levels with progression-free survival of patients with cervical squamous cell carcinoma

From: Clinical value of serum squamous cell carcinoma antigen levels in predicting chemosensitivity, lymph node metastasis, and prognosis in patients with cervical squamous cell carcinoma

Variable Mean survival times (months) χ2 P
SCC antigen levels before chemotherapy   0.054 0.817
 NACT group (n = 63) 38.02 (34.43, 41.61)   
 Conventional group (n = 39) 31.99 (29.25, 34.74)   
NACT group   0.0002 0.988
 Chemotherapy-insensitive group (n = 32) 36.34 (31.50, 41.19)   
 Chemotherapy-sensitive group (n = 31) 38.09 (33.07, 43.12)   
SCC antigen levels in NACT group before chemotherapy   12.148 < 0.001
  < 4.55 (n = 29) NA a   
  ≥ 4.55 (n = 34) NA a   
SCC antigen levels ≥4.55 before chemotherapy   3.256 0.071
 NACT group (n = 34) 30.21 (24.74, 35.67)   
 Conventional group (n = 22) 31.27 (28.21, 34.34)   
SCC antigen levels in NACT group after the first chemotherapy   13.954 < 0.001
  < 2.70 (n = 39) 43.34 (41.09, 45.58)   
  ≥ 2.70 (n = 24) 24.74 (18.80, 30.68)   
  1. a, in NACT group before chemotherapy, when SCC antigen levels < 4.55 ng/mL, 29 patients were survival and it is impossible to calculate the survival times of patients